Jul 10, 2024 · Twice-yearly injections of Lenacapavir showed overwhelming efficacy for preventing HIV infections compared to standard oral preventative HIV medicines, known as pre-exposure prophylaxis (PrEP). Additional trials are ongoing in Argentina, Brazil, Mexico, Peru, South Africa, Thailand and the United States.

Jan 27, 2021 · FDA approved CABENUVA (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension), co-packaged for intramuscular use. This is the first...

Jan 4, 2023 · Sunlenca is the first of a new class of drugs called capsid inhibitors to be FDA-approved for treating HIV-1. Sunlenca works by blocking the HIV-1 virus’ protein shell (the capsid), thereby interfering with multiple essential steps of the viral lifecycle.

Fortunately, researchers continue to search for new and better HIV treatments that can fill these gaps in care. Here’s a look at some of the most exciting options. When you have HIV, you go on a...

Mar 12, 2025 · Gilead researchers have developed 12 HIV medications, including the first single-tablet regimen to treat HIV, the first antiretroviral for pre-exposure prophylaxis (PrEP) to help reduce new HIV infections, and the first long-acting injectable HIV treatment medication administered twice-yearly.

Feb 18, 2025 · Gilead researchers have developed 12 HIV medications, including the first single-tablet regimen to treat HIV, the first antiretroviral for pre-exposure prophylaxis (PrEP) to help reduce new HIV infections, and the first long-acting injectable HIV treatment medication administered twice-yearly.

Mar 17, 2025 · Denison, who has lived with HIV for 35 years, told scientists at the meeting: “Your work saved my life.” But the conference also brought some hopeful news. Promising data suggest a drug could ward off HIV infection for a full year after a single injection, a potential breakthrough in so-called pre-exposure prophylaxis (PrEP).

Mar 19, 2025 · In the open-label extension phase of ALLIANCE, which is the first randomized clinical trial evaluating TAF- versus TDF-based regimens in treatment-naïve adults with HIV/HBV coinfection, week 48 outcomes indicated that Biktarvy induced high rates of HIV-1 (95.4%) and HBV (86.6%) virologic suppression in participants (n = 89) that switched to ...

HIV treatment in 2025 is more advanced than ever, with exciting new therapies and personalized care options helping people with HIV live longer, healthier lives. From long-acting injectables and chewable tablets to groundbreaking research on potential cures, the future of HIV care is bright.

Mar 9, 2025 · Real-world and implementation data highlight effectiveness of Cabenuva (cabotegravir + rilpivirine LA) and Apretude (cabotegravir LA (CAB LA) for PrEP), the only approved long-acting injectable therapies for HIV treatment and prevention, among broad range of communities; Late-breaking phase IIb data demonstrate the potential of an investigational new …